Acyclovir and Udenyca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Acyclovir (acyclovir) and Udenyca (pegfilgrastim-cbqv). Common drug interactions include neutropenic colitis among females and blood creatinine increased among males.

The phase IV clinical study analyzes what interactions people have when they take Acyclovir and Udenyca. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Acyclovir?

Acyclovir has active ingredients of acyclovir. It is often used in herpes simplex. eHealthMe is studying from 54,961 Acyclovir users. Check the latest studies of Acyclovir.

What is Udenyca?

Udenyca has active ingredients of pegfilgrastim-cbqv. eHealthMe is studying from 455 Udenyca users. Check the latest studies of Udenyca.



On Jul, 13, 2026

16 people who take Acyclovir and Udenyca together, and have interactions are studied.

Acyclovir and Udenyca drug interactions.

What are the common drug interactions of Acyclovir and Udenyca, by gender? *:

female:

  1. Neutropenic colitis (inflammation of the cecum, often with involvement of the ascending colon and ileum, a life threatening condition)
  2. Stomatitis (inflammation of mucous membrane of mouth)
  3. Confusional state
  4. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Neutropenia (an abnormally low number of neutrophils)
  7. Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
  8. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

male:

  1. Blood creatinine increased
  2. Fungal infection
  3. Abdominal discomfort
  4. Acute lymphocytic leukaemia (in remission)
  5. Aphthous ulcer (mouth ulcer)
  6. Bell's palsy (facial paralysis)
  7. Blindness
  8. Constipation
  9. Decreased appetite
  10. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

What are the common drug interactions of Acyclovir and Udenyca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abdominal discomfort
  2. Bell's palsy (facial paralysis)
  3. Blindness
  4. Constipation
  5. Decreased appetite
  6. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  7. Hypersomnia (excessive daytime sleepiness (eds))
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  9. Malignant ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen)
  10. Malignant neoplasm progression (cancer tumour came back)

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Neutropenic colitis (inflammation of the cecum, often with involvement of the ascending colon and ileum, a life threatening condition)
  2. Stomatitis (inflammation of mucous membrane of mouth)
  3. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  4. Confusional state
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Death
  7. Neutropenia (an abnormally low number of neutrophils)
  8. Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
  9. Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)
  10. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

What are the existing conditions these people have? *

  1. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 4 people, 25.00%
  2. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 18.75%
  3. Burkitt Lymphoma (cancer of the lymphatic system): 3 people, 18.75%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 18.75%
  5. High Blood Pressure: 3 people, 18.75%
  6. Nausea (feeling of having an urge to vomit): 2 people, 12.50%
  7. Anaemia (lack of blood): 2 people, 12.50%
  8. Dementia (madness): 2 people, 12.50%
  9. Diarrhea: 2 people, 12.50%
  10. High Blood Cholesterol: 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Acyclovir and Udenyca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Acyclovir and Udenyca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Acyclovir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Udenyca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Acyclovir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Udenyca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on acyclovir and pegfilgrastim-cbqv (the active ingredients of Acyclovir and Udenyca, respectively), and Acyclovir and Udenyca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: